GUÍA MANEJO ANTIRRETROVIRAL PERSONAS VIH

genotype 3 infection in HIV-seropositive patients. Clin Infect Dis.
2006;43(3), 365-372.
M.W. Fried, S.J. Hadziyannis, M. Shiffman, D. Messinger, S.
Zeuzem. Rapid virological response is a more important predictor
of sustained virological response (SVR) than genotype in patients
with chronic hepatitis C virus infection. Oral presentation. J
Hepatol. Supll 2, vol. 48. 43rdAnnual Meeting of EASL 2008.
Mallal S, Phillips E, Carosi G et al.HLA-B*5701 screening for
hypersensitivity to abacavir. N Engl J Med. 2008; 358(6), 568-
579.
Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial
toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001;
357: 280-281.
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M,
Marcellin P, et al. PEGASYS International Study Group.
Peginterferon-alpha2a and ribavirin combination therapy in
chronic hepatitis C: a randomized study of treatment duration and
ribavirin dose.Ann Intern Med. 2004 Mar 2;140(5):346-55.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman
M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin
compared with interferon alfa-2b plus ribavirin for initial
treatment of chronic hepatitis C: a randomised trial. Lancet. 2001
Sep 22;358(9286):958-65.
Zeuzem S. Heterogeneous virologic response rates to interferonbased
therapy in patients with chronic hepatitis C: who responds
less well? Ann Intern Med. 2004 Mar 2;140(5):370-81.
James Koziel M, Peters MG, Viral hepatitis in HIV infection:
current concepts. N Engl J Med.2007; 356: 1445.
Valdespino Jl, Condec, Olaiz fg y Cols. Seroprevalence of hepatitis
C among mexicans adults: and emerging public health problem.
Salud Publ Mex.2007; 49 (3).
Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of
chronic hepatitis B in co-infected patients. J Hepatol. 2006; 44:
S65-S70.
Christian Hoffmann and Fiona Mulcahy. ART 2007. In: Hoffman
C, Rockstroh JK, Kamps BS, editors. HIV Medicine 2007, 15th
ed. Hamburg, Bonn, Paris: Flying Publisher; 2007. p. 89-272.
Tsai NC. Practical management of chronic hepatitis B infection.
Semin Liver Dis. 2004; 24(suppl 1):71-6.
Lok AS, McMahon BJ. Chronic hepatitis B.
Hepatology.2001Dec;34:1225-41.
Ziol M, Handra-Luca A, Kettaneh A,et al. Noninvasive assessment
of liver fibrosis by measurement of stiffness in patients with
chronic hepatitis C. Hepatology.2005; 41(1): 48–54.
Castera L, Vergniol J, Foucher J. et al. Prospective comparison of
transient elastography, fibrotest, APRI, and liver biopsy for the
assessment of fibrosis in chronic hepatitis C.
Gastroenterology.2005;128(2):343–350.
Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive
methods to detect progression of fibrosis among HCV carriers
with normal aminotransferases. Hepatology.2005;42:838–45.
Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al.
Predicting cirrhosis risk based on the level of circulating hepatitis
B viral load. Gastroenterology. 2006;130:678-86.
Soriano V, Sheldon J, Belen R, Marina N. Confrontig chronic
hepatitis B vírus infection in HIV: new dianostic tools and more
weapons.AIDS.2006; 20: 451-453.
Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for
the management of chronic hepatitis B virus infection in the
United States: an update. Clin Gastroenterol Hepatol2006;4:936-
62.
Lok AS, McMahon BJ. Chronic hepatitis B: update of
recommendations. Hepatology.2004;39:857-61.
Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim
F, Mauss S, Rockstroh J. Care of HIV patients with chronic
hepatitis B: updated recommendations from the HIV Hepatitis B
virus international panel. AIDS.2008; 22:1399-1410.
Pillay D, Cane PA, Ratcliffe D, Atkins M, Cooper D. Evolution of
lamivudine-resistant hepatitis B virus and HIV-1 in co-infected
individuals: an analysis of the CAESAR study. AIDS. 2000; 14:
1111-1116.
McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug
entecavir - effects on HIV-1 replication and resistance. N Engl J
Med, 2007; 356(25):2614-21.
Panel of the European AIDS Clinical Society (EACS). Guidelines
for the Clinical Management and Treatment of Chronic Hepatitis
B and C co-infection in HIV-infected Adults. European AIDS
Clinical Society; Jun 2008. The European AIDS Clinical Society
Site; [PDF version].Disponible
enhttp://www.eacs.eu/guide/index.htmConsultado: 15-09-
2008.
Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis
in HIV and hepatitis B coinfection, despite lamivudine therapy as
partof HAART. Clin Infect Dis 2004; 39:133-135.
Lascar RM, Lopes AR, Gilson RJ, et al. Effect of HIV infection and
antiretroviral therapy on hepatitis B virus (HBV)-specific T cell
responses in patients who have resolved HBV infection. J Infect
Dis 2005; 191(7):1169-79.
Anexo VI
1. Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention
and treatment of opportunistic infections in HIV-infected adults
and adolescents: recommendations from CDC, the National
Institutes of Health, and the HIV Medicine Association of the
Infectious Diseases Society of America. MMWR Recomm Rep
2009; 58:1.
2. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent
tuberculosis infection in HIV infected persons. Cochrane
Database Syst Rev 2010; :CD000171.
3. Jordan TJ, Lewit EM, Montgomery RL, Reichman LB. Isoniazid as
preventive therapy in HIV-infected intravenous drug abusers. A
decision analysis. JAMA 1991; 265:2987.
4. Sterling TR, Bethel J, Goldberg S, et al. The scope and impact of
treatment of latent tuberculosis infection in the United States and
Canada. Am J Respir Crit Care Med 2006; 173:927.
5. Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of
an interferon-gamma release assay with tuberculin skin testing in
HIV-infected individuals. Am J Respir Crit Care Med. 2007;
175:737.
6. Zhang M, Gong J, Iyer DV, et al. T cell cytokine responses in
persons with tuberculosis and human immunodeficiency virus
infection. J Clin Invest. 1994; 94:2435.
7. Sutherland R, Yang H, Scriba TJ, et al. Impaired IFN-gammasecreting
capacity in mycobacterial antigen-specific CD4 T cells
during chronic HIV-1 infection despite long-term HAART. AIDS.
2006; 20:821.
8. Farhat M, Greenaway C, Pai M, Menzies D. False-positive
tuberculin skin tests: what is the absolute effect of BCG and nontuberculous
mycobacteria? Int J Tuberc Lung Dis. 2006; 10:1192.
9. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent
tuberculosis infection in HIV infected persons. Cochrane
Database Syst Rev. 2010 Jan 20;(1):CD000171.
10. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma
release assays for the diagnosis of latent tuberculosis infection in
HIV-infected individuals: a systematic review and meta-analysis.
J Acquir Immune Defic Syndr. 2011; 56:230.
11. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based
assays for the diagnosis of latent tuberculosis infection: an update.
Ann Intern Med. 2008; 149:177.
12. Brock I, Ruhwald M, Lundgren B, et al. Latent tuberculosis in HIV
positive, diagnosed by the M. tuberculosis specific interferongamma
test. Respir Res. 2006; 7:56.
13. Adams LV, Waddell RD, Von Reyn CF. T-SPOT.TB Test(R)
results in adults with Mycobacterium avium complex pulmonary
disease. Scand J Infect Dis. 2008; 40:196.
14. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-
month isoniazid preventive treatment for tuberculosis in adults
with HIV infection in Botswana: a randomised, double-blind,
placebo-controlled trial. Lancet 2011; 377:1588.
15. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to
prevent tuberculosis in adults with HIV infection. N Engl J Med.
2011; 365:11.
16. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent
tuberculosis infection in HIV infected persons. Cochrane
Database Syst Rev 2010; Jan 20;(1):CD000171.
17. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens
to prevent tuberculosis in Ugandan adults infected with the
human immunodeficiency virus. Uganda-Case Western Reserve
University Research Collaboration. N Engl J Med. 1997; 337:801.
18. Churchyard GJ, Fielding KL, Lewis JJ, et al. A trial of mass
isoniazid preventive therapy for tuberculosis control. N Engl J
Med 2014; 370:301.
19. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus
antiretroviral therapy to prevent tuberculosis: a randomised
double-blind, placebo-controlled trial. Lancet 2014.
20. Sterling TR, Villarino ME, Borisov AS, et al. Three months of
rifapentine and isoniazid for latent tuberculosis infection. N Engl
J Med. 2011; 365:2155.
21. Balcells ME, Thomas SL, Godfrey-Fausset P, Grant AD. Isoniazid
preventive therapy and risk for resistant tuberculosis. Emerg Infect
Dis. 2006;12(5):744-751.
183